Please ensure Javascript is enabled for purposes of website accessibility

Lexicon Pharma to Cut Around 45% of Workforce; CEO to Depart

By Eric Volkman – Jan 13, 2014 at 4:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Lexicon Pharmaceuticals will focus its efforts on late-stage drug development, which will lead to the loss of 115 jobs.

Lexicon Pharmaceuticals (LXRX) is narrowing its business focus in an effort that will lead to a substantial reduction in head count, and its CEO will also be departing.

The company announced that it will concentrate its resources on late-stage drug development programs. For the most part, this consists of two treatments it's currently developing -- one for diabetes, and the other for carcinoid syndrome. As a result of this new concentration, around 115 employees will no longer work at the firm. That's roughly 45% of the present workforce.

With these measures, Lexicon says it will reduce its expenses by a net amount of approximately $14 million for the balance of its fiscal 2014 and around $22 million annually going forward.

In the press release announcing the news, the firm quoted CEO Arthur Sands as saying that the new focus "increases Lexicon's financial strength and will enable the company to more effectively advance our key late-stage programs and to prepare for commercialization."

Sands will not stay in his current position. In the press release, the company revealed that he has "indicated his intention to develop a succession plan with the board of directors to identify a new chief executive officer for the next phase of Lexicon's growth." Sands will stay in his position until the board finds his replacement. 

Last month, Lexicon's share price swooned after the company reported disappointing results from its phase 2 study of LX1033, a treatment for irritable bowel syndrome. 

Fool contributor Eric Volkman has no position in Lexicon Pharmaceuticals. Nor does The Motley Fool. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Lexicon Pharmaceuticals Stock Quote
Lexicon Pharmaceuticals
$2.13 (%)

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.